TY - JOUR
T1 - High baseline lipoprotein(a) level as a risk factor for coronary artery calcification progression
T2 - Sub-analysis of a prospective multicenter trial
AU - Ida, Jun
AU - Kotani, Kazuhiko
AU - Miyoshi, Toru
AU - Nakamura, Kazufumi
AU - Kohno, Kunihisa
AU - Asonuma, Hirohiko
AU - Sakuragi, Satoru
AU - Doi, Masayuki
AU - Miki, Takashi
AU - Koyama, Yasushi
AU - Ito, Hiroshi
N1 - Funding Information:
We thank Takefumi Oka, MD, Tadahisa Uesugi, MD, Makoto Nakahama, MD, Ysuke Kawai, MD, Mitsuru Munemasa, MD, Natsuki Takahashi, MD, Naoki Mukohara, MD, Seiji Habara, MD, Yusuke Katayama, MD, Ritsuko Terasaka, MD, Atsushi Mima, MD, Hitoshi Matsubara, MD, Shingo Hosogi, MD, Masayuki Doi, MD, Masayuki Ueeda, MD, Norio Urabe, MD, Kazufumi Takeuchi, MD, Yasuharu Namba, MD, Tetsuya Sato, MD, Nobuyuki Yamada, MD, Masahito Taniguchi, MD, Yutaka Kajikawa, MD, Kouki Watanabe, MD, Kenichi Hisamatsu, MD, Hiroo Kobayashi, MD, and Kiyoaki Maekawa, MD, who were the PEACH investigators. We thank Kaoru Akazawa, Miyuki Fujiwara, and Masayo Ohmori for their technical assistance. This study was funded by the Japan Heart Foundation (No. 12090021).
Funding Information:
Acknowledgments. We thank Takefumi Oka, MD, Tadahisa Uesugi, MD, Makoto Nakahama, MD, Ysuke Kawai, MD, Mitsuru Munemasa, MD, Natsuki Takahashi, MD, Naoki Mukohara, MD, Seiji Habara, MD, Yusuke Katayama, MD, Ritsuko Terasaka, MD, Atsushi Mima, MD, Hitoshi Matsubara, MD, Shingo Hosogi, MD, Masayuki Doi, MD, Masayuki Ueeda, MD, Norio Urabe, MD, Kazufumi Takeuchi, MD, Yasuharu Namba, MD, Tetsuya Sato, MD, Nobuyuki Yamada, MD, Masahito Taniguchi, MD, Yutaka Kajikawa, MD, Kouki Watanabe, MD, Kenichi Hisamatsu, MD, Hiroo Kobayashi, MD, and Kiyoaki Maekawa, MD, who were the PEACH investigators. We thank Kaoru Akazawa, Miyuki Fujiwara, and Masayo Ohmori for their technical assistance. This study was funded by the Japan Heart Foundation (No. 12090021).
Publisher Copyright:
© 2018 by Okayama University Medical School.
PY - 2018
Y1 - 2018
N2 - Lipoprotein(a), or Lp(a), is a low-density lipoprotein-like particle largely independent of known risk factors for, and predictive of, cardiovascular disease (CVD). We investigated the association between baseline Lp(a) levels and the progression of coronary artery calcification (CAC) in patients with hypercholesterolemia undergoing statin therapy. This study was a sub-analysis of a multicenter prospective study that evaluated the annual progression of CAC under intensive and standard pitavastatin treatment with or without eicosapentaenoic acid in patients with an Agatston score of 1 to 999, and hypercholesterolemia treated with statins. We classified the patients into 3 groups according to CAC progression. A total of 147 patients (mean age, 67 years; men, 54%) were analyzed. The proportion of patients with Lp(a) > 30 mg/dL significantly increased as CAC progressed (non-progression; 5.4%, 0 < CAC progression ≦100; 7.7%, and CAC progression > 100; 23.6%). Logistic regression analysis showed that Lp(a) > 30 mg/dL was an independent predictor of the annual change in Agatston score > 100 (OR: 5.51; 95% CI: 1.28-23.68; p=0.02), even after adjusting for age, sex, hypertension, diabetes mellitus, current smoking, body mass index, and lipid-lowering medications. Baseline Lp(a) > 30 mg/dL was a predictor of CAC progression in this population of patients with hypercholesterolemia undergoing statin therapy.
AB - Lipoprotein(a), or Lp(a), is a low-density lipoprotein-like particle largely independent of known risk factors for, and predictive of, cardiovascular disease (CVD). We investigated the association between baseline Lp(a) levels and the progression of coronary artery calcification (CAC) in patients with hypercholesterolemia undergoing statin therapy. This study was a sub-analysis of a multicenter prospective study that evaluated the annual progression of CAC under intensive and standard pitavastatin treatment with or without eicosapentaenoic acid in patients with an Agatston score of 1 to 999, and hypercholesterolemia treated with statins. We classified the patients into 3 groups according to CAC progression. A total of 147 patients (mean age, 67 years; men, 54%) were analyzed. The proportion of patients with Lp(a) > 30 mg/dL significantly increased as CAC progressed (non-progression; 5.4%, 0 < CAC progression ≦100; 7.7%, and CAC progression > 100; 23.6%). Logistic regression analysis showed that Lp(a) > 30 mg/dL was an independent predictor of the annual change in Agatston score > 100 (OR: 5.51; 95% CI: 1.28-23.68; p=0.02), even after adjusting for age, sex, hypertension, diabetes mellitus, current smoking, body mass index, and lipid-lowering medications. Baseline Lp(a) > 30 mg/dL was a predictor of CAC progression in this population of patients with hypercholesterolemia undergoing statin therapy.
KW - Coronary artery calcification
KW - Hypercholesterolemia
KW - Lipoprotein(a)
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=85048861492&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048861492&partnerID=8YFLogxK
M3 - Article
C2 - 29925999
AN - SCOPUS:85048861492
VL - 72
SP - 223
EP - 230
JO - Acta Medica Okayama
JF - Acta Medica Okayama
SN - 0386-300X
IS - 3
ER -
